With reported performance validation on over 17,000 ultrasound images, Sonio Detect employs artificial intelligence (AI) to help ensure quality criteria for fetal ultrasound imaging of the brain and heart.
The Food and Drug Administration (FDA) has granted 510(k) clearance for Sonio Detect (Sonio), a fetal ultrasound software as a service (SaaS) platform that utilizes artificial intelligence (AI) to enhance the assessment of fetal heart and brain structures.
Emphasizing Sonio Detect’s robust accuracy in identifying ultrasound views and quality criteria, Sonio said the technology demonstrated a 92 percent sensitivity in performance validation testing on over 17,000 ultrasound images.
Sonio claimed the technology with Sonio Detect increases the efficiency of fetal heart and brain assessment and may facilitate improved diagnosis of fetal anomalies.
“Bringing the first easy to use, manufacturer agnostic and efficient quality control solution to all OBGYNs, (maternal fetal medicine specialists) and sonographers, we believe better screening will lead to better detection of potential anomalies or reassurance to provide better maternal care. Our goal is to transform prenatal care by providing a reliable tool that ensures better health outcomes for both mothers and babies,” noted Cecile Brosset, the chief executive officer and co-founder of Sonio.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.